logo VRX

Patient Characteristics

Patients Characteristics1

Patients receiving Voraxaze® with:

  • No pre-existing grade 4 toxicity before Voraxaze® administration
  • The appropriate increase in leucovorin rescue within 3 days after the start of HDMTX infusion

Administration of Voraxaze®

  • ≤ 96 hours after HDMTX exposure, n = 64
  • 96 hours after HDMTX exposure, n = 11

Inclusion Criteria1

Patients with MTX-included nephrotoxicity and delayed MTX excretion were eligible for treatment with Voraxaze®, if either of the following two conditions were met:

  • Plasma MTX concentration was ≥10 μmol/L ≥42 hours after the start of HDMTX infusion
  • sCr was ≥1.5 times the upper limit of normal or CrCl was ≤ 60mL/min/m2 and the plasma MTX concentration was ≥2 standard deviations above the mean ≥12 hours after MTX administration


Abbreviations: CrCl, creatinine clearance; HDMTX, high dose methotrexate; MTX, methotrexate; sCr, serum creatinine.